ADIM
LGND icon

Alpha DNA Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Alpha DNA Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16
Closed -$1K – 391
2021
Q1 		$1K Hold
16
– – ﹤0.01% 629
2020
Q4 		$0 Buy
+16
New +$912 ﹤0.01% 614

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Alpha DNA Investment Management's LGND Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2021, closing a stake of 16 shares — an estimated $1K sold.

Alpha DNA Investment Management first reported a position in LGND in Q4 2020 and held it in 2 quarters. The position peaked at $1K in Q1 2021. 212 funds tracked by Wall St. Rank hold LGND as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Ligand Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 16 Ligand Pharmaceuticals shares in Q2 2021, an estimated $1K.
  • Alpha DNA Investment Management first reported a position in Ligand Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Ligand Pharmaceuticals position peaked at $1K in Q1 2021.
  • 212 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.